Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Biodesix (BDSX) EPS (Weighted Average and Diluted) (2021 - 2025)

Biodesix's EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at -$0.43 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 58.25% year-over-year to -$0.43; the TTM value through Dec 2025 reached -$1.75, up 33.96%, while the annual FY2025 figure was -$4.67, 29.67% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.43 in Q4 2025 per BDSX's latest filing, up from -$1.16 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.08 in Q2 2024 to a low of -$4.52 in Q2 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.63, with a median of -$0.34 recorded in 2022.
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 91.16% in 2022, then tumbled 1044.44% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.49 in 2021, then soared by 32.65% to -$0.33 in 2022, then surged by 72.73% to -$0.09 in 2023, then crashed by 1044.44% to -$1.03 in 2024, then skyrocketed by 58.25% to -$0.43 in 2025.
  • Per Business Quant, the three most recent readings for BDSX's EPS (Weighted Average and Diluted) are -$0.43 (Q4 2025), -$1.16 (Q3 2025), and -$0.08 (Q2 2025).